Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.
Shota Omori, Hirotsugu Kenmotsu, Shogo Nomura et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized phase 3 trial evaluated daily low-dose carboplatin versus weekly carboplatin plus nab-paclitaxel in patients aged ≥75 years with locally advanced non-small cell lung cancer (LA-NSCLC). The study, conducted at 38 institutions in Japan, found that the median overall survival was 26.1 months for the carboplatin plus nab-paclitaxel arm, but the trial was terminated early for futility due to a Bayesian predictive probability of 8.0% for non-inferiority.
Key findings
- The estimated median overall survival was 26.1 months for the carboplatin plus nab-paclitaxel arm.
- The Bayesian predictive probability for non-inferiority was 8.0%, leading to early study termination.
- Patients receiving daily carboplatin reported better quality of life at 6 weeks (odds ratio, 0.39).
- Two treatment-related and seven non-cancer-related deaths occurred in the carboplatin plus nab-paclitaxel arm.
Why it matters
The findings reinforce the current standard of care for older patients with unresectable LA-NSCLC, highlighting the importance of treatment-related quality of life and survival outcomes in this population.